Borderline B12 with a self-prescribed folate supplement
A 58-year-old man who has followed a strict vegan diet for 9 years reports 6 months of fatigue, tingling in both feet, unsteadiness in the dark, and difficulty finding words. He began an over-the-counter folate supplement 3 months ago. Examination: pale, reduced vibration and position sense at the ankles, positive Romberg sign, brisk knee reflexes with bilateral Babinski signs, and impaired recall on a three-item memory test. Labs: Hgb 10.2 g/dL, MCV 116 fL, WBC 3.6 ×10⁹/L with hypersegmented neutrophils, platelets 118 ×10⁹/L, LDH elevated. Serum homocysteine and methylmalonic acid are both markedly elevated. Serum B12 is 190 pg/mL at a laboratory whose lower reference limit is 200.
1. Use the metabolite pattern and the blood count to distinguish vitamin B12 deficiency from folate deficiency, and explain the biochemical reason the two tests behave differently. How should the serum B12 of 190 be interpreted?
Read the worked answer
This is vitamin B12 deficiency, not folate deficiency.
The discriminating test is methylmalonic acid:
- Methionine synthase converts homocysteine to methionine and requires methylcobalamin (B12) or folate as the methyl donor. So homocysteine rises in both deficiencies.
- Methylmalonyl-CoA mutase requires adenosylcobalamin (B12 only). So methylmalonic acid rises only in B12 deficiency.
Pattern: elevated homocysteine + elevated MMA = B12 deficiency. Elevated homocysteine + normal MMA = folate deficiency. Both metabolites are elevated here, so this is B12.
Interpreting the B12 of 190 pg/mL: it is below the reference limit but close to it, and serum B12 is a poor test - it can be spuriously normal because of low transcobalamin, liver disease, or myeloproliferative states. In the presence of a compatible picture and elevated metabolites, a borderline value should be treated as deficient. A "low-normal" B12 never overrides positive MMA.
Marrow findings: macrocytosis with hypersegmented neutrophils plus a mild pancytopenia (leukopenia, thrombocytopenia) and elevated LDH is the signature of ineffective megaloblastic hematopoiesis, not marrow failure.
2. Explain the danger of the folate supplement he has already been taking, and state the neurologic findings you would monitor.
Read the worked answer
The folate trap / masking problem: folate can drive methionine synthase and partially correct the anemia while doing nothing for the methylmalonyl-CoA pathway, which is the pathway linked to neurologic injury. The blood count improves and the clinician is falsely reassured while subacute combined degeneration progresses. Giving folate alone to a B12-deficient patient can precipitate or accelerate neurologic deterioration.
Monitor for:
- Dorsal columns: loss of vibration and position sense, sensory ataxia, positive Romberg sign, worsening in the dark or with eyes closed.
- Corticospinal tracts: spasticity, hyperreflexia, Babinski signs, clonus, gait stiffening.
- Peripheral nerve: stocking-distribution numbness and burning (the tingling in his feet may be a mixed peripheral and cord picture).
- Cognition and affect: impaired recall, slowed processing, irritability - his memory complaint fits.
His examination already shows both dorsal column and corticospinal involvement. Do not interpret a rise in hemoglobin on folate as improvement; the neurologic examination is the outcome that matters.
3. Results of confirmatory testing will take several days. Decide whether to start treatment now, specify what you would give, and state what else must be checked during repletion.
Read the worked answer
Start treatment immediately - do not wait for confirmatory testing.
Reasons: the neurologic deficits are potentially irreversible and time-dependent; the metabolite pattern is already diagnostic; and a trial of therapy is itself part of the workup.
Regimen:
- Parenteral cyanocobalamin 1,000 mcg IM daily for about a week, then weekly for about 4 weeks, then monthly. This is the standard approach when neurologic involvement is present.
- High-dose oral 1,000–2,000 mcg daily is an acceptable alternative even in malabsorption, because a small fraction is absorbed passively - but parenteral therapy is preferred with active neurologic signs.
- Stop the folate supplement (or continue folate only alongside adequate B12).
Also check and act on:
- Potassium: brisk repletion drives potassium into cells and can precipitate hypokalemia - monitor during the first days.
- Reticulocyte count at 1 week as a response marker; LDH should fall.
- Cause of the deficiency: intrinsic factor antibodies, anti-parietal cell antibodies, and a careful assessment for pernicious anemia - a 9-year vegan diet explains the deficiency in this patient, but a second cause (pernicious anemia, metformin, proton-pump inhibitor use, ileal disease) may coexist and changes the long-term plan.
- Iron: iron deficiency can emerge as the marrow turns over and may blunt the hematologic response.
Reassess the neurologic examination at each visit; the hematologic response is fast, and the neurologic recovery is slower and often incomplete if treatment is delayed.